Diagnostic Test Package

The Arterial Health Diagnostic Test Package provides physicians superior arterial diagnostic capabilities by performing 5 key tests in one appointment.  This allows for addressing critical risk factors at the advent or early development of the disease.

Cardiovascular Disease Test

Carotid Duplex Scans

A non-invasive study of the common, external and internal carotid arteries using advanced ultrasound equipment.  Typically, 25-30 images of either side are captured for review and interpretation by qualified specialists.  This exam can include a review of the vertebral and subclavian arteries, if needed.  The ultrasound images reveal current levels of homogeneous, heterogeneous and calcified plaque.  This study is the standard of care for determining arterial blockage.

Lower Extremity Arterial Duplex

Lower Extremity Arterial DuplexPeripheral Arterial Duplex is a quick, non-invasive way to check for peripheral arterial disease (PAD).  PAD is a common circulatory problem in which the arteries to your limbs narrow due to atherosclerosis (plaque) causing reduced blood flow.  When PAD is developed, the extremities do not receive enough blood flow to keep up with demand. PAD is directly linked to narrowed arteries in the heart and brain, which can and will lead to an increased risk of heart attack, stroke, and transient ischemic attacks.

Spectral waveform analysis is taken from the bilateral anterior and posterior tibial arteries noting triphasic, biphasic, or monophasic waveforms and peak systolic velocities.  Normal waveforms and ankle-brachial indices are consistent with normal circulation throughout the lower extremities ruling out the diagnosis of PAD.

Carotid Intima-Media Thickness Test (arterial wall)

photo of arterial wall

Carotid Intima-Media Thickness (CIMT) is a measure of the two innermost layers of the carotid artery wall. Clinical studies over the last 20 years have shown that after factoring for age, gender, and ethnicity, individuals with advanced CIMT values have a greater risk of cardiovascular and cerebrovascular events than those with CIMT values judged to be normal for the comparable group.

The test is safe and painless. An ultrasound machine is used to measure the combined thicknesses of the intimal and medial layers of the carotid artery walls. The test is done on both sides of the neck.

The carotid arteries provide a “window” to the coronary arteries as they have similar risk factors. Carotid artery atherosclerosis provides insight to the risk and existence of coronary atherosclerosis in an individual. CIMT is an independent predictor of future cardiovascular events, including heart attacks, cardiac death, and stroke.  Arterial Health uses software based on the ARIC study data for comparative analysis of resulting measurements.

Terason T3000 used in EndoPat test

 Arterial Health uses state-of-the-art devices such as the Terason t3000 ultrasound machine.  This is an Apple MacBook laptop, adapted to hold an ultrasound controller board and sophisticated software.  The CIMT measuring software is based on the ARIC study, the largest public database of CIMT data and the accepted standard worldwide.

 

Terason t3000 logo

 

 

 

 

Endothelial Function Assessment via the Endo-PAT 2000

Megyn Kelly on Foxnews – latest news coverage on EndoPAT:  http://video.foxnews.com/v/2371966231001/can-your-fingers-predict-heart-disease  (NOTE – THIS VIDEO CLIPS STARTS WITH A 15 SECOND ‘ADVERTISEMENT’ FOR A MEDICAL CENTER)

For more than a decade Endothelial Dysfunction has been recognized by the medical community as the earliest detectable stage of cardiovascular disease. It is treatable and reversible. The Endo-PAT2000, by Itamar Medical, is the leading medical device for noninvasive endothelial function assessment. Based on Nobel-Prize winning science, it is FDA-cleared, CE-marked and used in preeminent clinical institutions, research centers and pharmaceutical clinical phase studies in over 40 countries. It is incorporated into numerous multi-center and population-based studies such as the Framingham Heart Study. Research using Endo-PAT has yielded more than 300 articles in peer- reviewed journals and abstracts.

EndoPat Diagnostic Machine

Endo-PAT is based on noninvasive Peripheral Arterial Tone (PAT) signal technology. It measures endothelium-mediated changes in vascular tone using unique bio-sensors placed on the fingertips. These changes in arterial tone are elicited by creating a down-stream hyperemic response induced by a standard 5-minute occlusion of the brachial artery. Measurements from the contra-lateral arm are used to control for concurrent non-endothelial dependent changes in vascular tone. The automatically calculated result is an index of endothelial function; Reactive Hyperemia Index

 

 

 

ADVANCED BLOOD DIAGNOSTICS:

VAP® Cholesterol Test

vap_logo_rt

  • The VAP Test is the only single cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement and secondary and emerging risk factors.  It is the only commercially available single test that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology guidelines
  • The accuracy of the Vertical Auto Profile or VAP Cholesterol Test is verified every six months by performing a split sample comparison with the Core Laboratory for Clinical Studies at Washington University School of Medicine in St. Louis, MO, which is one of few reference laboratories for lipoprotein proficiency analysis.

The VAP Test provides accurate, comprehensive results, identifying people at risk for cardiovascular disease with a detection rate that is more than twice that of standard lipid panels.  This enables clinicians to more accurately assess their patient’s risk for CHD and thus better manage their treatment leading to improved outcomes. The test does not require a patient to fast in preparation.

The VAP Test is the most accurate and comprehensive lipid profile that effectively addresses these medical concerns:

 Limitations of the Standard Lipid Profile

  • The Standard Lipid Profile was developed in 1972, when 300mg/dL was considered “normal” cholesterol and only 3% of population had an LDL less than 100mg/dL in the study used to define the Standard Lipid Profile.  In contrast, current NCEP ATP III Guidelines push LDL to less than 100mg/dL in many patients and the updates to ATP III recommend less than 70mg/dL as optional in very high risk patients.
  • The Standard Lipid Profile is generally agreed to be inaccurate in non-fasting patients and inconsistent when triglycerides become greater than 200-250mg/dL.
  • The Standard Lipid Profile has been shown to have a 40 percent predictive value for coronary heart disease (CHD).1 This low predictive value is cause for increasing concern among clinicians and it is been shown that 80 percent of patients in the Framingham Study who had a cardiovascular event had lipid results similar to the population that was event-free.2

Friedewald Chart

  ADDITIONAL ANALYSIS

  • Apoliproteins
  • Glucose
  • Hb
  • HbA1c
  • C-Reactive Protein-hs
  • Lp-Pla1
  • Vitamin D
  • 25-Hydroxy
  • TSH
  • Metabolic Syndrome/Insulin Resistance Assessment

 

 

 

facebooktwittergoogle_pluspinterestlinkedinmail